Q60. The first FDA-approved humanized monoclonal antibody, a…

Q60. The first FDA-approved humanized monoclonal antibody, adalimumab (Humira), resulted in a ∼ 12% incidence of a therapeutic problem in a small percentage of patients with rheumatoid arthritis. The problem was that they developed anti-therapeutic antibodies (ATA). This problem was subsequently reduced to ∼2–3% for patients receiving methotrexate which is a non-steroid anti-inflammatory and a mild immunosuppressant. What type of difference most likely led to the ATA response? 

Q67. (BONUS QUESTION 02) A 3-year-old boy is brought to the…

Q67. (BONUS QUESTION 02) A 3-year-old boy is brought to the pediatrician due to recurrent respiratory infections and chronic diarrhea. His parents report he has had multiple episodes of pneumonia and otitis media since infancy. Physical exam reveals enlarged tonsils and cervical lymphadenopathy. Labs show: IgM: 850 mg/dL (rr: 40-230 mg/dL), IgG:

Q61. A researcher is studying antibody diversity developing…

Q61. A researcher is studying antibody diversity developing in B cells. They observe that during V(D)J recombination, the enzyme terminal deoxynucleotidyl transferase (TdT) adds non-templated nucleotides at the junctions between gene segments. In which region of the antibody heavy chain is this junctional diversity most likely to directly affect the amino acid sequence?